Leading sight loss charity the Macular Society has responded to the decision not to approve the first potential treatment for geographic atrophy (GA) or late stage dry aged-related macular degeneration.
The decision is a significant setback for those affected by GA, who have been waiting for progress in managing this challenging condition. Drug manufacturer Apellis, has revealed that the MHRA has rejected Syfovre (pegcetacoplan) for use in the UK, as a treatment for GA.
While the MHRA did recognise the effect of Syfovre on slowing the rate of progression of GA, they were concerned about whether it meaningfully improved patients’ ability to see and manage daily tasks during the trial period.
The drug was approved by the Food and Drug Administration for use in the US in 2023.
GA causes gradual and irreversible damage to the retina, leading to severe sight loss. While the decision not to approve this treatment is disappointing, the Macular Society remains optimistic about ongoing research and the development of other potential therapies.
Commenting on the decision, director of research at the Macular Society, Dr Peter Bloomfield, said: "This is undoubtedly disappointing news for people living with GA, many of whom have been hoping for a breakthrough. However, we want to reassure patients that this is not the end of the road. There are several promising treatments in development, and we remain committed to supporting research and advocating for better options in the future.
"For now, our priority is to continue providing support to those affected by GA and ensure they have access to the resources and information they need. The Macular Society will also keep funding research to drive progress in this area."
The Macular Society is dedicated to improving the lives of those with GA and macular disease through support, advocacy, and research. While this decision marks a setback, it highlights the need for continued collaboration among researchers, healthcare providers, and policymakers to address the urgent needs of patients.
